Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation

Journal of Clinical Investigation

Volumn 120, Issue 10, 2010, Pages 3702-3712

  Martínez Barricarte, Rubén ^a   Heurich, Meike ^b   Valdes Cañedo, Francisco ^c   Vazquez Martul, Eduardo ^c   Torreira, Eva ^a   Montes, Tamara ^a   Tortajada, Agustín ^a   Pinto, Sheila ^a   Lopez Trascasa, Margarita ^d   Morgan, B Paul ^b   Llorca, Oscar ^a   Harris, Claire L ^b   De Córdoba, Santiago Rodríguez ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; DENSE DEPOSIT DISEASE; DISEASE COURSE; ELECTRON MICROSCOPY; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; GLOMERULUS BASEMENT MEMBRANE; HEMATURIA; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPATHOGENESIS; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MESANGIUM; MUTATIONAL ANALYSIS; PEDIGREE ANALYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEINURIA;

ADULT; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C3B; COMPLEMENT FACTOR H; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; MALE; MIDDLE AGED; MUTATION;

EID: 77957827919     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI43343     Document Type: Article

References (39)

1. Amara U, et al. Interaction between the coagulation and complement system. Adv Exp Med Biol. 2008;632:71-79.
2. Lachmann PJ. The amplification loop of the complement pathways. Adv Immunol. 2009;104:115-149.
3. Walport MJ. Complement- second of two parts. N Engl J Med. 2001;344(15):1140-1144.
4. Walport MJ. Complement- first of two parts. N Engl J Med. 2001;344(14):1058-1066.
5. Smith RJH, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007;18(9):2447-2456.
6. Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens. 2007;16(3):204-212.
7. Ault BH, et al. Human factor H deficiency. J Biol Chem. 1997;272(40):25168-25175.
8. Dragon-Durey MA, et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol. 2004;15(3):787-795.
9. Zipfel PF, Heinen S, Józsi M, Skerka C. Complement and diseases: Defective alternative pathway control results in kidney and eye diseases. Mol Immunol. 2006;43(1-2):97-106.
10. Licht C, et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 2006;70(1):42-50.
11. HøgÅsen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest. 1995;95(3):1054-1061.
12. Pickering MC, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet. 2002;31(4):424-428.
13. Rose KL. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest. 2008;118(2):608-618.
14. Pickering MC, et al. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci U S A. 2006;103(25):9649-9654.
15. Harris CL, Abbott RJM, Smith RA, Morgan BP, Lea SM. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). J Biol Chem. 2005;280(4):2569-2578.
16. Janssen BJC, et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature. 2005;437(7058):505-511.
17. Gros P, Milder FJ, Janssen BJC. Complement driven by conformational changes. Nat Rev Immunol. 2008;8(1):48-58.
18. Torreira E, Tortajada A, Montes T, Rodríguez de Córdoba S, Llorca O. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase. Proc Natl Acad Sci U S A. 2009;106(3):882-887.
19. Torreira E, Tortajada A, Montes T, Rodriguez de Cordoba S, Llorca O. Coexistence of closed and open conformations of complement factor b in the alternative pathway C3bB(Mg2+) proconvertase. J Immunol. 2009;183(11):7347-7351.
20. Wu J, Wu YQ, Ricklin D, Janssen BJC, Lambris JD, Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol. 2009;10(7):728-733.
21. Gordon DL, Kaufman RM, Blackmore TK, Kwong J, Lublin DM. Identification of complement regulatory domains in human factor H. J Immunol. 1995;155(1):348-356.
22. Kuhn S, Skerka C, Zipfel PF. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. J Immunol. 1995;155(12):5663-5670.
23. Liszewski MK, Leung MK, Schraml B, Goodship THJ, Atkinson JP. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol. 2007;44(7):1559-1568. (Pubitemid 44792750)
24. Richards A, et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol. 2007;44(1-3):111-122.
25. Rooijakkers SHM, et al. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol. 2009;10(7):721-727.
26. Janssen BJC, Halff EF, Lambris JD, Gros P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem. 2007;282(40):29241-29247.
27. Wiesmann C, et al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature. 2006;444(7116):217-220.
28. Katschke KJ, et al. Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J Biol Chem. 2009;284(16):10473-10479.
29. Bexborn F, Andersson PO, Chen H, Nilsson B, Ekdahl KN. The tick-over theory revisited: Formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol Immunol. 2008;45(8):2370-2379.
30. Rodriguez de Cordoba S, Goicoechea de Jorge E. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol. 2008;151(1):1-13. (Pubitemid 350230999)
31. Goicoechea de Jorge E, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2007;104(1):240-245.
32. Gonzalez-Rubio C, Ferreira-Cerdan A, Ponce IM, Arpa J, Fontan G, Lopez-Trascasa M. Complement Factor I deficiency associated with recurrent meningitis coinciding with menstruation. Arch Neurol. 2001;58(11):1923-1928. (Pubitemid 33044263)
33. Hakobyan S, et al. Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(5):1983-1990.
34. Abarrategui-Garrido C, Martinez-Barricarte R, Lopez-Trascasa M, Rodriguez de Cordoba S, Sanchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood. 2009;114(19):4261-4271.
35. Rother U. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Methods. 1982;51(1):101-107. (Pubitemid 12125433)
36. Lesavre PH, Hugli TE, Esser AF, Müller-Eberhard HJ. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol. 1979;123(2):529-534. (Pubitemid 9203384)
37. Fremeaux-Bacchi V, et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet. 2004;41(6):e84.
38. Perez-Caballero D, et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet. 2001;68(2):478-484. (Pubitemid 32147816)
39. Richards A, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2003;100(22):12966-12971.